Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

1. Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive

Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive Naltrexone/bupropion (Mysimba▼): risk of adverse reactions that could affect ability to drive - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Naltrexone/bupropion (Mysimba▼): risk of adverse reactions that could affect ability to drive Advise patients that naltrexone/bupropion has been associated with adverse reactions (...) such as dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks. Advise patients not to drive if they suspect their ability may be impaired. Published 19 August 2019 From: Therapeutic area: , Contents Advice for healthcare professionals: people taking naltrexone/bupropion may commonly experience dizziness or somnolence, and may rarely experience loss of consciousness or seizure these effects would pose a risk to their ability to drive or operate machinery

2019 MHRA Drug Safety Update

2. Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation Full Text available with Trip Pro

Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban.Assess participants (...) ' understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides.A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey

2018 Drugs - real world outcomes

3. Bupropion

Bupropion Top results for bupropion - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for bupropion The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

4. Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients

Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients Published 7 May 2018 Statement of Advice: naltrexone hydrochloride / bupropion hydrochloride 8mg / 90mg prolonged-release tablets (Mysimba ® ) SMC2086 Orexigen Therapeutics Ireland Limited 6 April 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation naltrexone / bupropion (Mysimba ® ) is not recommended

2018 Scottish Medicines Consortium

5. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial Full Text available with Trip Pro

Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial Quitting smoking is enhanced by the use of pharmacotherapies, but concerns have been raised regarding the cardiovascular safety of such medications.To compare the relative cardiovascular safety risk of smoking cessation treatments.A double-blind, randomized, triple-dummy, placebo- and active-controlled trial (Evaluating Adverse Events in a Global Smoking Cessation Study [EAGLES]) and its (...) nontreatment extension trial was conducted at 140 multinational centers. Smokers, with or without established psychiatric diagnoses, who received at least 1 dose of study medication (n = 8058), as well as a subset of those who completed 12 weeks of treatment plus 12 weeks of follow up and agreed to be followed up for an additional 28 weeks (n = 4595), were included.Varenicline, 1 mg twice daily; bupropion hydrochloride, 150 mg twice daily; and nicotine replacement therapy, 21-mg/d patch with tapering.The

2018 EvidenceUpdates

6. Benefits and harms of Mysimba© (naltrexone-bupropion) in the management of overweight and obesity: a systematic review and meta-analysis of unpublished clinical study reports

Benefits and harms of Mysimba© (naltrexone-bupropion) in the management of overweight and obesity: a systematic review and meta-analysis of unpublished clinical study reports Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

7. Impact of CYP2B6*6 allele on bupropion exposure

Impact of CYP2B6*6 allele on bupropion exposure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect

2018 PROSPERO

8. Naltrexone / bupropion (Mysimba) - for the management of weight in adult patients

Naltrexone / bupropion (Mysimba) - for the management of weight in adult patients Naltrexone/bupropion (Mysimba®) for the management of weight in adults The NCPE has issued a recommendation regarding the cost-effectiveness of naltrexone/bupropion (Mysimba®). Following assessment of the applicant’s submission, the NCPE recommends that naltrexone/bupropion (Mysimba®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified (...) in the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Orexigen Therapeutics Ireland Limited) economic dossier on the cost effectiveness of naltrexone/bupropion (Mysimba®). The NCPE uses a decision framework to systematically assess whether a technology is cost-effective. This includes clinical effectiveness and health related quality of life benefits, which the new treatment may provide

2018 Pediatric Endocrine Society

9. Naltrexone?bupropion for managing overweight and obesity

Naltrexone?bupropion for managing overweight and obesity Naltre Naltrex xone–bupropion for managing one–bupropion for managing o ov verweight and obesity erweight and obesity T echnology appraisal guidance Published: 12 December 2017 nice.org.uk/guidance/ta494 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naltrexone–bupropion for managing overweight and obesity (TA494) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 The technology 5 3 Committee discussion 6

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

10. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Full Text available with Trip Pro

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all (...) adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.To assess the effects and safety of bupropion for the treatment of adults with ADHD.We searched

2017 Cochrane

11. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Full Text available with Trip Pro

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD.To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD.In a retrospective cohort study, we used data from 14 350 patients with COPD included (...) in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012. Patients were followed up for 6 months to compare incident cardiovascular (ie, ischaemic heart disease, stroke, heart failure, peripheral vascular disease and cardiac arrhythmias

2017 EvidenceUpdates

12. Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults [Cochrane protocol]

Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

13. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. Few cardiovascular outcomes trials have been conducted for obesity treatments. Withdrawal of 2 marketed drugs has resulted in controversy about the cardiovascular safety of obesity agents.To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular (...) -based weight management program was provided to all participants. Participants were randomized to receive placebo (n=4454) or naltrexone, 32 mg/d, and bupropion, 360 mg/d (n=4456).Time from randomization to first confirmed occurrence of a MACE. The primary analysis planned to assess a noninferiority hazard ratio (HR) of 1.4 after 378 expected events, with a confidential interim analysis after approximately 87 events (25% interim analysis) to assess a noninferiority HR of 2.0 for consideration

2016 JAMA Controlled trial quality: predicted high

14. Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness

Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness (...) Published on: March 8, 2016 Project Number: RC0747-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of nicotine replacement therapy versus bupropion or varenicline in the general population of tobacco users? What is the comparative clinical effectiveness of nicotine replacement therapy, bupropion or varenicline versus placebo in the general population of tobacco users? Key Message Ten relevant

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Role of maclobemide, buspirone, bethanechol, bupropion and cyproheptadine in treatment of sexual dysfunction

Role of maclobemide, buspirone, bethanechol, bupropion and cyproheptadine in treatment of sexual dysfunction Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO

16. Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss

Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss Prescrire IN ENGLISH - Spotlight ''Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss'', 1 October 2015 {1} {1} {1} | | > > > Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss FEATURED REVIEW On average, obese or overweight patients taking naltrexone + bupropion lose only a few kilograms. In contrast, its neuropsychiatric adverse effects are numerous and potentially severe. There is also a risk of hypertension, cardiac arrhythmia and gastrointestinal adverse effects. Full review (4 pages) available for download by subscribers. Abstract Weight loss and its long-term maintenance are mainly based on dietary

2015 Prescrire

17. Does any antidepressant besides bupropion help smokers quit?

Does any antidepressant besides bupropion help smokers quit? Does any antidepressant besides bupropion help smokers quit? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does any antidepressant besides bupropion help smokers quit? View/ Open Date 2014-11 Format Metadata Abstract Q: Does any antidepressant besides (...) bupropion help smokers quite? Evidence-based answer: Yes, nortriptyline approximately doubles smoking cessation rates, an effect comparable to bupropion. Adding nortriptyline to nicotine replacement therapy (NRT) doesn’t improve rates further (strength of recommendation [SOR]: A, systematic review of randomized controlled trials [RCTs]). Selective serotonin reuptake inhibitors (SSRIs; fluoxetine, paroxetine, sertraline, citalopram), venlafaxine, mono-amine oxidase inhibitors (MAOIs; moclobemide

2015 Clinical Inquiries

18. Naltrexone and Bupropion Combination: A New Promising Therapy for Long Term Weight Loss

Naltrexone and Bupropion Combination: A New Promising Therapy for Long Term Weight Loss "Naltrexone and Bupropion Combination: A New Promising Therapy for Long" by Sam Q. Nguyen < > > > > > Title Author Date of Graduation Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Being overweight or obese is a growing health concern not just in the United States, but worldwide (...) dependence, and bupropion is commonly used for depression. Separately, these two medications have been shown to reduce weight weakly; this review aims to evaluate the benefits of naltrexone and bupropion used in combination for weight loss. Method: An exhaustive literature search using the search engines Medline-OVID, CINAHL, and Web of Science combining keywords naltrexone, bupropion, and weight loss was conducted. Eligible criteria include research with naltrexone and bupropion combination therapy

2015 Pacific University EBM Capstone Project

19. Bupropion versus other antidepressive agents for depression [Cochrane Protocol]

Bupropion versus other antidepressive agents for depression [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

20. Mysimba - naltrexone / bupropion

Mysimba - naltrexone / bupropion 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 December 2014 EMA/805547/2015 Committee for Medicinal Products for Human Use (CHMP) Mysimba (naltrexone/bupropion) Procedure No. EMEA/H/C/003687 Applicant: Orexigen Therapeutics Ireland Limited Assessment report for an initial marketing (...) /A Not applicable NCA Noncompartmental analysis NB Naltrexone hydrochloride /Bupropion hydrochloride combination NB16 Naltrexone PR 16 mg/Bupropion PR 360 mg NB32 Naltrexone PR 32 mg/Bupropion PR 360 mg NB48 Naltrexone PR 48 mg/Bupropion PR 360 mg ng Nanogram NICE The National Institute for Health and Care Excellence NNH Number needed to harm NNT Number needed to treat NOS Not otherwise specified OCT2 Organic Cation Transporter-2 PAWC Pharmacologically weighted composite PBO Placebo PCS Potentially clinically

2015 European Medicines Agency - EPARs